These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 16203654)
21. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris. Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868 [TBL] [Abstract][Full Text] [Related]
22. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847 [TBL] [Abstract][Full Text] [Related]
23. Pharmacology of different progestogens: the special case of drospirenone. Sitruk-Ware R Climacteric; 2005 Oct; 8 Suppl 3():4-12. PubMed ID: 16203650 [TBL] [Abstract][Full Text] [Related]
24. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives]. Cianci A; De Leo V Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and pharmacodynamics of drospirenone-estradiol combination hormone therapy product coadministered with hydrochlorothiazide in hypertensive postmenopausal women. Karara AH; Hanes V; Alonso A; Ni P; Poola N; Silang R; Blode H; Preston RA J Clin Pharmacol; 2007 Oct; 47(10):1292-302. PubMed ID: 17906162 [TBL] [Abstract][Full Text] [Related]
26. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. Rübig A Climacteric; 2003 Oct; 6 Suppl 3():49-54. PubMed ID: 15018248 [TBL] [Abstract][Full Text] [Related]
27. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy. Popp AW; Bodmer C; Senn C; Fuchs G; Kraenzlin ME; Wyss H; Birkhaeuser MH; Lippuner K Maturitas; 2006 Jan; 53(2):191-200. PubMed ID: 16368472 [TBL] [Abstract][Full Text] [Related]
28. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. White WB; Pitt B; Preston RA; Hanes V Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434 [TBL] [Abstract][Full Text] [Related]
29. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Sørensen MB; Rosenfalck AM; Højgaard L; Ottesen B Obes Res; 2001 Oct; 9(10):622-6. PubMed ID: 11595778 [TBL] [Abstract][Full Text] [Related]
30. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A Menopause; 2006; 13(3):377-86. PubMed ID: 16735934 [TBL] [Abstract][Full Text] [Related]
31. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial. Schaefers M; Muysers C; Alexandersen P; Christiansen C Menopause; 2009; 16(3):559-65. PubMed ID: 19423999 [TBL] [Abstract][Full Text] [Related]
32. The contraceptive profile of a new oral contraceptive with antimineralocorticoid and antiandrogenic effects. Foidart JM Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():25-33. PubMed ID: 11246599 [TBL] [Abstract][Full Text] [Related]
33. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis. Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479 [TBL] [Abstract][Full Text] [Related]
34. Menopause and cardiovascular disease: the evidence. Rosano GM; Vitale C; Marazzi G; Volterrani M Climacteric; 2007 Feb; 10 Suppl 1():19-24. PubMed ID: 17364594 [TBL] [Abstract][Full Text] [Related]
35. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss. Choi HJ; Im JA; Kim SH Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334 [TBL] [Abstract][Full Text] [Related]
36. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms. Ylikorkala O Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649 [No Abstract] [Full Text] [Related]
37. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490 [TBL] [Abstract][Full Text] [Related]
38. Drospirenone-containing hormone therapy for postmenopausal women. Perspective on current data. Archer DF J Reprod Med; 2007 Feb; 52(2 Suppl):159-64. PubMed ID: 17477110 [TBL] [Abstract][Full Text] [Related]
39. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739 [TBL] [Abstract][Full Text] [Related]
40. Characteristics of nasal epithelial cells in naturally postmenopausal women receiving hormone therapy with 1 mg 17beta-estradiol and 2 mg drospirenone: a prospective study. Caruso S; Serra A; Grillo C; Maiolino L; Agnello C; Di Mari L; Cianci A Menopause; 2008; 15(5):963-6. PubMed ID: 18391834 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]